Flow Cytometric Diagnosis of Acute Leukemia and Aberrant Antigen: Sohag University Experience

Hamed, Elham O.; El-Deen, Abeer Fakher

doi:10.4236/ojbd.2018.82005

Cited by 5 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the contrary of ours, other studies noted different distribution of the aberrant marker expression, many of them reported that CD7 was the most common lymphoid associated antigen in AML followed by CD19 (16, 27,32,33,36,41,57,58). Others noted that CD19 was the most common expressed lymphoid antigen followed by CD7 (18,53).…”

Section: Aberrant Expression In Aml Patientscontrasting

confidence: 98%

“…There was a male predominance in our AL patients, which is in accordance with most studies that noted that the males are more affected (27,(31)(32)(33)(34). In our study there was a pediatric predominance in AL, this may be due to that ALL was more common than AML.…”

Section: Monosomysupporting

confidence: 91%

“…Some studies agree with the present study and noted that ALL was more common than AML followed by BAL (5, 39-41). To the contrary of ours, some studies noted that AML was more common than ALL (16, 32,33,42). From our T-ALL patients, ETP-ALL represented 12.7%, which agrees with the results of many studies in which ETP-ALL ranged from 9.7% to 20% of their T-ALL cases (43)(44)(45)(46)(47).…”

Section: Monosomysupporting

confidence: 88%

See 2 more Smart Citations

Expression of aberrant markers in acute leukemia at South Egypt Cancer Institute: A retrospective study

2021

SECI Oncology Journal

View full text Add to dashboard Cite

Background: Aberrant phenotypes in acute leukemia (AL) have variable frequency and their prognostic relevance is controversial and dissimilar results have been reported by different groups. Objectives: To determine frequency of aberrant marker expression in acute leukemia at South Egypt Cancer Institute (SECI) and to relate these expression with patient outcome and cytogenetic abnormality. Patients and Methods: A retrospective study was conducted at SECI over a period of ten years. Total 1134 AL patients of both genders and all age groups were included in the study, of them 458 were diagnosed as acute myeloid leukemia (AML), 494 were diagnosed as B-acute lymphoblastic leukemia (B-ALL), 157 were diagnosed as T-ALL and 25 were diagnosed as biphenotypic AL (BAL). Results: Aberrant phenotypes were found in 91 (19.9%) cases of AML, 148 (30%) cases of

show abstract

Section: Aberrant Expression In Aml Patientscontrasting

confidence: 98%

Section: Monosomysupporting

confidence: 91%

Section: Monosomysupporting

confidence: 88%

See 1 more Smart Citation

Expression of aberrant markers in acute leukemia at South Egypt Cancer Institute: A retrospective study

2021

SECI Oncology Journal

View full text Add to dashboard Cite

show abstract

“…In a retrospective analysis of data from 144 patients with AL, it was discovered that 61.8% of patients with AL had AML and that AML-M2 (31.8%) was the most prevalent FAB subtype in the AML group, followed by M4-M5 (27.3%). CD7 was the most frequently expressed lymphoid antigen in AML (25%) [ 17 ].…”

Section: Discussionmentioning

confidence: 99%

The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients

Raza¹,

Fatima²,

Noor³

et al. 2022

Cureus

View full text Add to dashboard Cite

BackgroundAberrant phenotype expression in acute myeloid leukemia (AML) may be due to genetic defects and is associated with a poor prognosis. CD7 is the first T-cell-associated antigen to be expressed during Tlymphocyte maturation. Aberrant expression of CD7 in AML influences clinical response, remission rate, and overall survival in these patients. ObjectiveTo determine the frequency of aberrant CD7 expression in patients with AML. Materials and methodsThis cross-sectional study was performed over a period of 12 months from July 2020 to June 2021 in the Hematology Department, Chughtai Lab, Lahore. This study included 120 patients who were newly diagnosed with AML. The following tests were performed for included patients: complete blood count (CBC), peripheral blood smear analysis, and flow cytometric analysis using a blood sample or bone marrow aspirate. Blast cells were analyzed for aberrant CD7 expression. Calculation of the sample size was performed by using the Select Statistics calculator. All statistical analyses were performed using SPSS ver. 23 software (IBM Corp., Armonk, NY). Data were expressed as frequencies, means ± standard deviation (SD), and percentages. ResultsOf 120 patients newly diagnosed with AML, the CD7 antigen was aberrantly expressed in 36 cases (30%). Of these patients, the AML2 subtype was the most common type of AML with aberrant CD7 expression, followed by AML M4, AML M1, M3, AML M5, and AML M0, respectively. ConclusionIn our study, aberrant CD7 expression occurred at a high frequency in acute myeloid leukemia. Thus, this marker should be added to the current flow cytometry panels.

show abstract

“…However, when abnormal blasts are present, they tend to keep expressing this antigen in later developmental stages of cell maturation. 4 In adult ALL CD34 expression is associated with poor prognosis, as compared to paediatric ALL. Clinical significance and disease prognosis are dependent on CD34 expression among ALL.…”

Section: Introductionmentioning

confidence: 99%

Frequency of Cd34 Expression in Acute Lymphoblastic Leukaemia and Its Correlation With Clinicopathological Characteristics: A Single Centre Experience From Pakistan

Bashir

Hassan²,

Waheed³

et al. 2022

J Ayub Med Coll Abbottabad

View full text Add to dashboard Cite

Background: This study was carried out to determine the frequency of CD34 positivity in acute lymphoblastic leukaemia (B-ALL) in our population and to report its association with the clinicopathological profilet the time of diagnosis. Methods: The cross-sectional study was conducted at National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi, Pakistan, from March 2020 till December 2020.Newly diagnosed patients were selected, from both genders and all age groups. Relevant history and findings of physical examination were recorded. Immunohistochemistry was done on trephine biopsy and molecular studies were carried on bone marrow aspirates or peripheral blood samples. Results: Out of 105 patients enrolled, 67(63.8%) were males, with a male to female ratio (M: F) 1.8:1. Of the total patients, 62 (59.04%) were above 15 years of age. CD34 was expressed in 73 (69.5%) cases. Lymphadenopathy, splenomegaly, and hepatomegaly were separately noted in context to CD 34 expression in 22 (66.6%), 24 (64.8%), and 14 (58.3%) patients, respectively. CNS disease was seen in a total of 3(2.75%) subjects, in which 2 (66.6%) of the patients had CD34 expression. Total 81 patients in our study fall into the high-risk group out of which CD 34 expression was seen in 58(71.6%) subjects. Cytogenetic analysis, BCR-ABL p190, and MLL gene rearrangement were investigated in all participants. Cytogenetic analysis revealed an abnormality in 20 (19%) cases out of which 13 (17.8%) cases were from CD34 positive group. Conclusion: Our study reported CD34 expression in more than two-thirds of cases. High-risk disease was significantly associated with CD34 expression.

show abstract

Flow Cytometric Diagnosis of Acute Leukemia and Aberrant Antigen: Sohag University Experience

Cited by 5 publications

References 21 publications

Expression of aberrant markers in acute leukemia at South Egypt Cancer Institute: A retrospective study

Expression of aberrant markers in acute leukemia at South Egypt Cancer Institute: A retrospective study

The Frequency of Aberrant CD7 Antigen Expression in Acute Myeloid Leukaemia Patients

Frequency of Cd34 Expression in Acute Lymphoblastic Leukaemia and Its Correlation With Clinicopathological Characteristics: A Single Centre Experience From Pakistan

Contact Info

Product

Resources

About